MARKET

FOLD

FOLD

Amicus Therapeut
NASDAQ
14.43
0.00
0.00%
After Hours: 14.43 0 0.00% 16:20 03/26 EDT
OPEN
14.43
PREV CLOSE
14.43
HIGH
14.43
LOW
14.42
VOLUME
1.56M
TURNOVER
--
52 WEEK HIGH
14.43
52 WEEK LOW
5.51
MARKET CAP
4.53B
P/E (TTM)
-164.1638
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at FOLD last week (0316-0320)?
Weekly Report · 3d ago
Weekly Report: what happened at FOLD last week (0309-0313)?
Weekly Report · 03/16 09:12
BioMarin price target lowered to $85 from $97 at BofA
TipRanks · 03/11 10:36
Weekly Report: what happened at FOLD last week (0302-0306)?
Weekly Report · 03/09 09:12
Amicus Therapeutics President and CEO Bradley L Campbell Disposes of Common Shares
Reuters · 03/05 00:55
Amicus Therapeutics Inc. Held Special Stockholder Meeting
Reuters · 03/03 21:55
Amicus Stockholders Approve BioMarin Acquisition at Special Meeting
TipRanks · 03/03 21:34
BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients
Benzinga · 03/02 11:10
More
About FOLD
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.

Webull offers Amicus Therapeutics, Inc. stock information, including NASDAQ: FOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FOLD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FOLD stock methods without spending real money on the virtual paper trading platform.